Global sales and Copaxone lift Teva
This article was originally published in Scrip
In reviewing its financial results for the year, Teva Pharmaceutical Industries' chief executive Shlomo Yanai called 2010 "a great year for Teva", in which the firm became the generics leader in Europe, moved to complete its integration of the German company Ratiopharm, increased its presence in emerging markets, and had record sales of its multiple sclerosis drug Copaxone (glatiramer acetate).
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.